Literature DB >> 22234465

Angiotensin II reduces food intake by altering orexigenic neuropeptide expression in the mouse hypothalamus.

Tadashi Yoshida1, Laura Semprun-Prieto, Richard D Wainford, Sergiy Sukhanov, Daniel R Kapusta, Patrice Delafontaine.   

Abstract

Angiotensin II (Ang II), which is elevated in many chronic disease states such as end-stage renal disease and congestive heart failure, induces cachexia and skeletal muscle wasting by increasing muscle protein breakdown and reducing food intake. Neurohormonal mechanisms that mediate Ang II-induced appetite suppression are unknown. Consequently, we examined the effect of Ang II on expression of genes regulating appetite. Systemic Ang II (1 μg/kg · min) infusion in FVB mice rapidly reduced hypothalamic expression of neuropeptide Y (Npy) and orexin and decreased food intake at 6 h compared with sham-infused controls but did not change peripheral leptin, ghrelin, adiponectin, glucagon-like peptide, peptide YY, or cholecystokinin levels. These effects were completely blocked by the Ang II type I receptor antagonist candesartan or deletion of Ang II type 1a receptor. Ang II markedly reduced phosphorylation of AMP-activated protein kinase (AMPK), an enzyme that is known to regulate Npy expression. Intracerebroventricular Ang II infusion (50 ng/kg · min) caused a reduction of food intake, and Ang II dose dependently reduced Npy and orexin expression in the hypothalamus cultured ex vivo. The reduction of Npy and orexin in hypothalamic cultures was completely prevented by candesartan or the AMPK activator 5-aminoimidazole-4-carboxamide ribonucleoside. Thus, Ang II type 1a receptor-dependent Ang II signaling reduces food intake by suppressing the hypothalamic expression of Npy and orexin, likely via AMPK dephosphorylation. These findings have major implications for understanding mechanisms of cachexia in chronic disease states such as congestive heart failure and end-stage renal disease, in which the renin-angiotensin system is activated.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22234465      PMCID: PMC3281527          DOI: 10.1210/en.2011-1764

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  60 in total

Review 1.  Central nervous system control of food intake.

Authors:  M W Schwartz; S C Woods; D Porte; R J Seeley; D G Baskin
Journal:  Nature       Date:  2000-04-06       Impact factor: 49.962

2.  Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure.

Authors:  E Roig; F Perez-Villa; M Morales; W Jiménez; J Orús; M Heras; G Sanz
Journal:  Eur Heart J       Date:  2000-01       Impact factor: 29.983

3.  Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I.

Authors:  M Brink; S R Price; J Chrast; J L Bailey; A Anwar; W E Mitch; P Delafontaine
Journal:  Endocrinology       Date:  2001-04       Impact factor: 4.736

Review 4.  Candesartan cilexetil: an angiotensin II-receptor blocker.

Authors:  S See; A L Stirling
Journal:  Am J Health Syst Pharm       Date:  2000-04-15       Impact factor: 2.637

5.  Angiotensin II upregulates protein phosphatase 2Cα and inhibits AMP-activated protein kinase signaling and energy balance leading to skeletal muscle wasting.

Authors:  A Michael Tabony; Tadashi Yoshida; Sarah Galvez; Yusuke Higashi; Sergiy Sukhanov; Bysani Chandrasekar; William E Mitch; Patrice Delafontaine
Journal:  Hypertension       Date:  2011-08-15       Impact factor: 10.190

6.  The effect of angiotensin-converting enzyme inhibition using captopril on energy balance and glucose homeostasis.

Authors:  Annette D de Kloet; Eric G Krause; Dong-Hoon Kim; Randall R Sakai; Randy J Seeley; Stephen C Woods
Journal:  Endocrinology       Date:  2009-06-04       Impact factor: 4.736

Review 7.  ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial.

Authors:  Rainer Düsing; Felicity Sellers
Journal:  Curr Med Res Opin       Date:  2009-09       Impact factor: 2.580

Review 8.  Mechanisms of cancer cachexia.

Authors:  Michael J Tisdale
Journal:  Physiol Rev       Date:  2009-04       Impact factor: 37.312

9.  IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting.

Authors:  Liping Zhang; Jie Du; Zhaoyong Hu; Guofeng Han; Patrice Delafontaine; Gabriela Garcia; William E Mitch
Journal:  J Am Soc Nephrol       Date:  2009-01-21       Impact factor: 10.121

Review 10.  Candesartan cilexetil in the treatment of chronic heart failure.

Authors:  Jean-Philippe Baguet; Gilles Barone-Rochette; Yannick Neuder
Journal:  Vasc Health Risk Manag       Date:  2009-04-08
View more
  28 in total

1.  Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1-7)/Mas-dependent pathway.

Authors:  Johanna Schuchard; Martina Winkler; Ines Stölting; Franziska Schuster; Florian M Vogt; Jörg Barkhausen; Christoph Thorns; Robson A Santos; Michael Bader; Walter Raasch
Journal:  Br J Pharmacol       Date:  2015-06-12       Impact factor: 8.739

2.  Renin-angiotensin-aldosterone system in insulin resistance and metabolic syndrome.

Authors:  Undurti N Das
Journal:  J Transl Int Med       Date:  2016-07-07

Review 3.  Control of energy balance by the brain renin-angiotensin system.

Authors:  Kristin E Claflin; Justin L Grobe
Journal:  Curr Hypertens Rep       Date:  2015-05       Impact factor: 5.369

4.  THE RENIN-ANGIOTENSIN SYSTEM AND THE BIOLOGY OF SKELETAL MUSCLE: MECHANISMS OF MUSCLE WASTING IN CHRONIC DISEASE STATES.

Authors:  Patrice Delafontaine; Tadashi Yoshida
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

5.  RAS-Mediated Adaptive Mechanisms in Cardiovascular Tissues: Confounding Factors of RAS Blockade Therapy and Alternative Approaches.

Authors:  Rukhsana Gul; Maya Ramdas; Chirag H Mandavia; James R Sowers; Lakshmi Pulakat
Journal:  Cardiorenal Med       Date:  2012-10-27       Impact factor: 2.041

6.  An Intronic Enhancer Element Regulates Angiotensin II Type 2 Receptor Expression during Satellite Cell Differentiation, and Its Activity Is Suppressed in Congestive Heart Failure.

Authors:  Tadashi Yoshida; Patrice Delafontaine
Journal:  J Biol Chem       Date:  2016-10-18       Impact factor: 5.157

Review 7.  Skeletal muscle protein metabolism in human heart failure.

Authors:  Damien M Callahan; Michael J Toth
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2013-01       Impact factor: 4.294

Review 8.  Opposing tissue-specific roles of angiotensin in the pathogenesis of obesity, and implications for obesity-related hypertension.

Authors:  Nicole K Littlejohn; Justin L Grobe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-10-21       Impact factor: 3.619

9.  Enhanced angiotensin receptor-associated protein in renal tubule suppresses angiotensin-dependent hypertension.

Authors:  Hiromichi Wakui; Kouichi Tamura; Shin-Ichiro Masuda; Yuko Tsurumi-Ikeya; Megumi Fujita; Akinobu Maeda; Masato Ohsawa; Kengo Azushima; Kazushi Uneda; Miyuki Matsuda; Kenichiro Kitamura; Shinichi Uchida; Yoshiyuki Toya; Hiroyuki Kobori; Kiyotaka Nagahama; Akio Yamashita; Satoshi Umemura
Journal:  Hypertension       Date:  2013-03-25       Impact factor: 10.190

10.  Angiotensin type 1a receptors in the paraventricular nucleus of the hypothalamus protect against diet-induced obesity.

Authors:  Annette D de Kloet; Dipanwita Pati; Lei Wang; Helmut Hiller; Colin Sumners; Charles J Frazier; Randy J Seeley; James P Herman; Stephen C Woods; Eric G Krause
Journal:  J Neurosci       Date:  2013-03-13       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.